5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>Molecular biology technics for the detection <strong>of</strong> influenza have proventheir utility on the occasion <strong>of</strong> 2009 pandemic episode. The objective <strong>of</strong>this study was to evaluate the sensitivity <strong>of</strong> a fully automated molecularassay for the detection <strong>of</strong> influenza A and B: the Diagenode FluA/B assayoptimized for use on the automated BD MAX. The evaluation has beenperformed on 3 reference strains (2012/2013 vaccine strains), diluted from10 1 to 10 8 . 132 clinical samples positive for influenza A or influenza Bfrom 2011 2012 winter season were also retrospectively tested. Thesesamples were previously tested positive using our NIC reference technicsfor the detection <strong>of</strong> influenza A and influenza B and were stored at 20 ◦ C.All samples were tested on BD MAX and results were compared with those<strong>of</strong> our NIC reference technics. On reference strains, there was a perfectconcordance <strong>of</strong> BD MAX and NIC technics for the detection <strong>of</strong> A/H1N1strain. For A/H3N2 and B strains, there was a slight decrease in sensitivityon the last or two last dilutions, corresponding to a detection limit (Ctvalues >38). All types <strong>of</strong> samples tested (naso pharyngeal aspirates, nasalswabs and bronchoalveolar lavages) had valid results. The internal controlwas highly reproducible. 120 influenza A positive samples were tested.6 were not detected by BD MAX including 4 with high Ct values (35 to37). After a second test performed on these 6 samples, 3 were detectedpositive by BD MAX. 12 influenza B positive samples were tested; 4were not detected (all with high Ct values from 36 to 39) and 1 wasdetected after a second test. The limit <strong>of</strong> detection <strong>of</strong> the FluA/B molecularassay on BD MAX is satisfactory and proves its potential value for routinedetection <strong>of</strong> influenza viruses. The FluA/B assay on BD MAX appears tobe an interesting, sensitive, fully automated test for the routine moleculardetection <strong>of</strong> influenza viruses.REF 521Strategies to overcome invalid RespiFinder ® SMART 22 results causedby amplification inhibitionBart PEETERS, Isabel MICALESSI, Annick SMISMANS, Britt VANMEENSEL, Johan FRANSLaboratory <strong>of</strong> Clinical Microbiology, Imelda hospital, Bonheiden, BEL-GIUMThe RespiFinder ® SMART 22 assay (PathoFinder) is a multiplex PCR,detecting and differentiating 18 respiratory viruses and 4 bacteria. Aninternal control is included in the assay to assess amplification inhibition.A result is reported as invalid when the internal control is not amplified anda negative result is obtained for the 22 respiratory pathogens. This assay,which is performed in our daily routine, exhibits an inhibition rate <strong>of</strong> 5.9%.To circumvent false negative results due to inhibition, the manufacturerrecommends sample pretreatment with dithiothreitol or dilution <strong>of</strong> thesample extract. The aim <strong>of</strong> our study was to evaluate an alternative samplepretreatment procedure to avoid repeat testing <strong>of</strong> samples with invalidresults. First, 10 nasopharyngeal swab samples were retested after a onetime freeze thaw cycle with freezing for at least 15 h and all invalid resultswere resolved. After that, the minimum freezing time was determined on4 samples and a 30 min step was already sufficient to resolve the inhibitionproblem. Finally, a one time freeze thaw cycle was performed on 3 positivesamples and this pretreatment did not have any effect on the outcome <strong>of</strong> theassay. In conclusion, invalid results for the RespiFinder SMART 22 assaymay be avoided by subjecting all samples to a one time freeze thaw cyclewith a freezing step <strong>of</strong> at least 30 min. This sample pretreatment provides afast, low cost and easy to apply solution to prevent amplification inhibitionand to obtain higher turnaround times.REF 522Development <strong>of</strong> a new diagnostic tool for the detection <strong>of</strong> HumanCoronaviruses & Human Parainfluenzaviruses in a duplex RT PCRCécile RESA, Jérôme BES, Manon DUBE, Lionel GARNIER, MatthieuVIGNOLES, Stéphane MAGRO, Côme BARRANGERbioMérieux Site de Verniolle, Verniolle, FRANCEObjectives: Human Coronavirus (HCoV) and Parainfluenzaviruses(HPIV) are frequently involved in respiratory infections in young children,the elderly, and the immunodepressed. The bioMérieux HCoV/HPIVr gene ® real time PCR assay allows the detection <strong>of</strong> the 4 HCoV species(NL63, OC43, HKU1 & 229E) and the 4 HPIV species (HPIV 1; 2; 3 &4) with a high sensitivity.Methods: Nucleic acids were extracted from 200 L <strong>of</strong> nasopharyngealspecimens, after a Proteinase K pre treatment, on NucliSENS ®easyMAG TM and eluted in 50 L. 0.15 L <strong>of</strong> reverse transcriptase wasadded to 15 L <strong>of</strong> HCoV/HPIV r gene ® amplification premix. Then 10 L<strong>of</strong> eluted samples were added. HCoV and HPIV were detected at 530 nm& 560 nm respectively on Bio Rad Dx Real Time System.Results: On the Coronavirus QCMD 2012 Panel, all samples (10) werecorrectly identified. On the Parainfluenzavirus QCMD 2012 Panel, 9 <strong>of</strong>10 samples were correctly identified. Analytical Sensitivity study on the4 HCoV and the 4 HPIV species was performed in respiratory specimens.This study shows a high level <strong>of</strong> sensitivity for each parameter. Intra/interassay variability studies were carried out on HCoV and HPIV cultured cellsdiluted in nasopharyngeal negative samples. Coefficients <strong>of</strong> variation wereunder 2.5% (intra assay) and 4.0% (inter assay). Specificity study showedno cross reaction among 56 other respiratory viruses/bacteria.Conclusion: The high quality associated with its compatibility with themajor extraction and real time PCR platforms allows an immediate integration<strong>of</strong> HCoV/HPIV r gene ® 71 045 in most routine diagnostic labs.REF 523Equivalent performance results in S<strong>of</strong>ia fluorescent immunoassayanalyzer for Respiratory Syncytial Virus (SOFIA FIA RSV ® )toPCRtests in infantsAstrid VABRET 1,2,3 , Cecile RESA 3 , Julia DINA 1,2,3 , Amélie HEBERT 2 ,Celine TOURNUS 1 , Jean Baptiste DAVY 1,3 , Fabien MISZCZAK 1,3 ,Stephanie GOUARIN 1 , Joëlle PETITJEAN 3 , Jacques BROUARD 3,41 University Hospital <strong>of</strong> Caen, Laboratory <strong>of</strong> <strong>Virology</strong>, Caen, FRANCE;2 Reference Natioanl Center for Paramyxoviridae and Measles, Caen,FRANCE; 3 EA4655, University <strong>of</strong> Caen Basse Normandie, Caen,FRANCE; 4 University Hospital <strong>of</strong> Caen, Pediatric Department, Caen,FRANCERespiratory Syncytial Virus (RSV) is a common ubiquitous pathogen responsiblefor cold like symptoms in most adults and children. In infants,RSV is more likely to move into the lower respiratory tract and has beendetected in the majority <strong>of</strong> infants hospitalized for bronchiolitis during theRSV season. S<strong>of</strong>ia FIA RSV (Quidel, San Diego, CA) is an automatedrapid diagnostic test (RDT) that may improve the performance <strong>of</strong> classicalmanual RDT. The objective was to assess its performances with aprotocol in “real life laboratory” conditions. Four hundred and one (401)nasal swabs were sampled from patients <strong>of</strong> different groups <strong>of</strong> age duringthe RSV season. All these fresh samples were tested for RSV using directimmun<strong>of</strong>luorescence assay (DFA), S<strong>of</strong>ia FIA RSV, and PCR test. In allVi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013S265
5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>PCR positive respiratory samples, a standardized viral load (expressed asRSV RNA copies per 100 cells) was calculated using the kit Cell controlr gene ® Biomerieux. The S<strong>of</strong>ia FIA RSV displayed sensitivities <strong>of</strong> 78.8%(from 47.3% to 95%, in patients >2 years old and in infants, respectively)as opposed to PCR. The negative predictive value was 91.3% (from 89%to 96.6% in >2 years old and in infants, respectively). The cell loads in the123 respiratory specimens were between 3 and 5 Log10 cells per PCR. Nosignificant difference is observed in the cell loads in respiratory specimensfrom patients <strong>of</strong> different age groups. Nevertheless, the respiratory viralloads dramatically decreased in patients above 2 years <strong>of</strong> age. S<strong>of</strong>ia FIARSV ® is a sensitive and specific method with a high negative predictivevalue for patients <strong>of</strong> different age groups. Its performances prove equivalentto molecular tests in infants throughout the RSV circulation perioddue to high respiratory viral loads in this group. This fact can be explainedby the quasi systematic RSV primo infection before the age <strong>of</strong> 2 years.Methods: Nasopharyngeal swabs were prelevated from patients with acuterespiratory illness admitted from November 2012 to March 2013. Thesamples were tested with xTAG Respiratory Virus Panel Fast (Luminex).Results: A total <strong>of</strong> 227 samples were received, most <strong>of</strong> them (77.3%) frompediatric (0 14 years old) patients. More than half (56.3%) <strong>of</strong> the sampleswere positive for at least one virus, the predominant viruses being influenzaA and influenza B. Adenovirus, RSV and Rhinovirus/Enterovirus (RV/EV)were detected most frequently in children less than 5 years old. Elevensamples (8.5%) were positive for two viruses and one sample was positivefor three viruses. Co infection was significantly associated (p=0.02)with age under 5 years. Adenovirus and RV/EV were more frequentlydetected with other viruses, and all the viruses <strong>of</strong> the panel (influenza,parainfluenza, RSV, adenovirus, RV/EV, Coronavirus, Metapneumovirus,Bocavirus) were identified in co infections.Conclusion: Co infections with two or more respiratory viruses are <strong>of</strong>tendetected in pediatric patients with acute respiratory illness.REF 524The role <strong>of</strong> newly discovered viruses in the development <strong>of</strong> lowerrespiratory tract infections in KuwaitSahar ESSA 1 , Haya ALTAWALAH 1 , Abdulla OWAYED 2 , MossaKHADADHA 3 , Nasser BEHBEHANI 3 , Widad AL NAKIB 11 Department <strong>of</strong> Microbiology/Faculty <strong>of</strong> Medicine/Kuwait University,Kuwait, KUWAIT; 2 Department <strong>of</strong> Pediatrics/Faculty <strong>of</strong> Medicine/Kuwaituniversity, Kuwait, KUWAIT; 3 Department <strong>of</strong> Medicine/Faculty <strong>of</strong> Medicine/Kuwaituniversity, Kuwait, KUWAITIntroduction: More than 80% <strong>of</strong> the cases <strong>of</strong> respiratory tract infectionsare viral in origin. Although mostly causing self limited upper respiratorytract infections (URTI), they can be associated with serious lower respiratoryinfections (LRTI) with a high level <strong>of</strong> morbidity, particularly inchildren. Little is known about the role <strong>of</strong> newly discovered viruses in thedevelopment <strong>of</strong> URTI and LRTI in Kuwait and the Gulf region. Methods:The aim <strong>of</strong> this study is to investigate the role <strong>of</strong> seven newly discoveredviruses which include coronaviruses (HCoV) NL63, OC43, and 229E,human metapneumovirus (hMPV), bocavirus, human polyomaviruses WU(WUV) and KI (KIV) by using sensitive molecular techniques.Results: Seven hundred thirty five hospitalized patients were screenedduring three and a half year period, from September, 2010 to April, 2013.Of the 285 patients with viral respiratory infection HCoV OC43 was detectedin twenty five patients (8.8%), both HCoV 229E and bocavirus weredetected in fourteen patients (4.9%), hMPV in fifteen patients (5.3%),WUV in ten patients (3.8%), KIV in four patients (1.4%), and HCoVNL63, was not detected in any <strong>of</strong> our patients’ samples.Conclusion: We conclude that newly discovered viruses do play a rolein the development <strong>of</strong> both URTI and serious LRTI in Kuwait. Rapididentification <strong>of</strong> viral infections can help control nosocomial transmission,reduce overall antibiotic use and improve the treatment and managements<strong>of</strong> these infections.REF 525Multiple respiratory viral co infections in patients with acute respiratoryinfectionDragos FLOREA 1 , Angelica VISAN 1,2 , Anca DRAGANESCU 1 ,George JUGULETE 1,2 , Monica LUMINOS 1,2 , Dan OTELEA 11 National Institute for Infectious Diseases “Matei Bals”, Bucharest,ROMANIA; 2 University <strong>of</strong> Medicine and Pharmacy “Carol Davila”,Bucharest, ROMANIAObjective: the aim <strong>of</strong> the study was to investigate the prevalence <strong>of</strong> respiratoryviruses and the rate <strong>of</strong> viral co infection in patients hospitalizedwith acute respiratory infection in “Matei Bals” Institute.REF 526High proportion <strong>of</strong> multiple infections with respiratory viruses inyoung children with acute respiratory tract infectionsAtsushi KAIDA 1 , Hideyuki KUBO 1 , Nobuhiro IRITANI 1 , Koh IchiTAKAKURA 1 , Jun Ichiro SEKIGUCHI 1 , Minori OHYAMA 1 , UraraKOHDERA 2 , Masao TOGAWA 3,4 , Kiyoko AMO 3 , Masashi SHIOMI 3 ,Seiji P YAMAMOTO 1 , Kaoru GOTO 1 , Atsushi HASE 1 , TsutomuKAGEYAMA 51 Osaka City Institute <strong>of</strong> Public Health and Environmental Sciences,Osaka, JAPAN; 2 Nakano Children’s Hospital, Osaka, JAPAN; 3 OsakaCity General Hospital, Osaka, JAPAN; 4 Osaka City Sumiyoshi Hospital,Osaka, JAPAN; 5 Influenza Virus Research Center, National Institute <strong>of</strong>Infectious Diseases, Tokyo, JAPANObjectives: Respiratory virus is a major etiologic agent <strong>of</strong> acute respiratorytract infections (ARTIs) in young children. This study was conductedto detect multiple respiratory viruses and to analyze their co infection andmutual association using statistical analysis.Methods: During January 2010 – December 2011, 1,044 respiratory clinicalspecimens were obtained from children (< 6 years <strong>of</strong> age) with ARTI.To detect viral genes, multiplex real time PCR was conducted for respiratoryviruses (human metapneumovirus [hMPV], respiratory syncytial virus[RSV A, B], human parainfluenza virus types 1–4 [HPIV 1–4], humanbocavirus 1 [HBoV 1], human coronavirus [229E, OC43, HKU1, NL63],influenza virus [A, A (H1N1)2009, B, C], human adenovirus [HAdV],human enterovirus, and human rhinovirus [HRV]).Results: The 1,414 viruses were detected from 891 (85.3%) specimens,<strong>of</strong> which 388 (43.5%) specimens were multiple virus positive (2 viruses,279;=3 viruses, 109). The most detected was HRV (n=390). The proportion<strong>of</strong> multiple virus positives was higher in the 0–35 month age group. Thecombinations <strong>of</strong> HPIV 1 and HPIV 3, HPIV 1 and RSV A, HPIV 3 andhMPV, hMPV and RSV A, hMPV and FLUA (H1N1) 2009, RSV A andRSV B, and HRV and FLUA (H1N1) 2009 were negatively correlated. Incontrast, HAdV and HBoV 1 were positively correlated.Conclusions: Young children are highly susceptible to respiratory viruses.Viral co infections are common.REF 527Respiratory viruses in patient with acute respiratory tract infectionsin AYDIN, TURKEYSevin KIRDAR 1 , Neriman AYDIN 1 , Ayse YENIGUN 2 , EmelCEYLAN 31 Adnan Menderes University, Department <strong>of</strong> Medical Microbiology,Aydin, TURKEY; 2 Adnan Menderes University, Department <strong>of</strong> PediatricDiseases, Aydin, TURKEY; 3 Adnan Menderes University, Department <strong>of</strong>Pulmonary Medicine, Aydin, TURKEYS266 Vi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013
- Page 3 and 4:
Contents5 th European Congress of V
- Page 5 and 6:
i r o l o g i eList of Keynote Spea
- Page 7 and 8:
i r o l o g i eList of Chairpersons
- Page 9 and 10:
i r o l o g i eWelcomeWelcome to th
- Page 11 and 12:
5 th European Congress of VirologyY
- Page 13 and 14:
i r o l o g i eExhibitorsThe indust
- Page 15:
i r o l o g i eFacilities for the 5
- Page 18 and 19:
i r o l o g i eGeneral Information
- Page 20 and 21:
PROGRAMME AT A GLANCEWednesday 11th
- Page 22 and 23:
5 th European Congress of VirologyW
- Page 24 and 25:
5 th European Congress of VirologyW
- Page 26 and 27:
5 th European Congress of VirologyW
- Page 28 and 29:
5 th European Congress of VirologyW
- Page 30 and 31:
5 th European Congress of VirologyW
- Page 32 and 33:
Scientific Programme -Saturday 14 t
- Page 34 and 35:
5 th European Congress of Virology1
- Page 36 and 37:
5 th European Congress of VirologyW
- Page 38 and 39:
5 th European Congress of VirologyW
- Page 40 and 41:
5 th European Congress of VirologyW
- Page 42 and 43:
5 th European Congress of VirologyW
- Page 44 and 45:
5 th European Congress of VirologyW
- Page 46 and 47:
5 th European Congress of VirologyW
- Page 48 and 49:
5 th European Congress of VirologyT
- Page 50 and 51:
5 th European Congress of VirologyT
- Page 52 and 53:
5 th European Congress of VirologyT
- Page 54 and 55:
5 th European Congress of VirologyR
- Page 56 and 57:
5 th European Congress of VirologyR
- Page 58 and 59:
5 th European Congress of Virologyw
- Page 60 and 61:
5 th European Congress of VirologyT
- Page 62 and 63:
5 th European Congress of VirologyR
- Page 64 and 65:
5 th European Congress of Virologyt
- Page 66 and 67:
5 th European Congress of VirologyR
- Page 68 and 69:
5 th European Congress of VirologyT
- Page 70 and 71:
5 th European Congress of VirologyA
- Page 72 and 73:
5 th European Congress of Virologyp
- Page 74 and 75:
5 th European Congress of VirologyR
- Page 76 and 77:
5 th European Congress of VirologyF
- Page 78 and 79:
5 th European Congress of VirologyF
- Page 80 and 81:
5 th European Congress of Virologyc
- Page 82 and 83:
5 th European Congress of VirologyF
- Page 84 and 85:
5 th European Congress of VirologyF
- Page 86 and 87:
5 th European Congress of Virologyt
- Page 88 and 89:
5 th European Congress of VirologyH
- Page 90 and 91:
5 th European Congress of VirologyF
- Page 92 and 93:
5 th European Congress of VirologyR
- Page 94 and 95:
5 th European Congress of VirologyR
- Page 96 and 97:
5 th European Congress of VirologyS
- Page 98 and 99:
5 th European Congress of VirologyS
- Page 100 and 101:
5 th European Congress of VirologyS
- Page 102 and 103:
5 th European Congress of VirologyS
- Page 104 and 105:
5 th European Congress of VirologyA
- Page 106 and 107:
5 th European Congress of Virology1
- Page 108 and 109:
5 th European Congress of Virology1
- Page 110 and 111:
5 th European Congress of VirologyS
- Page 112 and 113:
5 th European Congress of VirologyS
- Page 114 and 115:
5 th European Congress of VirologyS
- Page 116 and 117:
5 th European Congress of VirologyS
- Page 118 and 119:
Virologie 2013, 17 (supplément 2)
- Page 120 and 121:
5 th European Congress of VirologyA
- Page 122 and 123:
5 th European Congress of Virology0
- Page 124 and 125:
5 th European Congress of Virology0
- Page 126 and 127:
5 th European Congress of VirologyH
- Page 128 and 129:
5 th European Congress of Virologys
- Page 130 and 131:
5 th European Congress of Virology0
- Page 132 and 133:
5 th European Congress of Virologyf
- Page 134 and 135:
5 th European Congress of VirologyE
- Page 136 and 137:
5 th European Congress of Virologyt
- Page 138 and 139:
5 th European Congress of VirologyA
- Page 140 and 141:
5 th European Congress of Virologyp
- Page 142 and 143:
5 th European Congress of Virology0
- Page 144 and 145:
5 th European Congress of Virologyi
- Page 146 and 147:
5 th European Congress of Virologyr
- Page 148 and 149:
5 th European Congress of Virologyi
- Page 150 and 151:
5 th European Congress of Virologyp
- Page 152 and 153:
5 th European Congress of Virology3
- Page 154 and 155:
5 th European Congress of VirologyR
- Page 156 and 157:
5 th European Congress of Virology0
- Page 158 and 159:
5 th European Congress of Virologyt
- Page 160 and 161:
5 th European Congress of VirologyB
- Page 162 and 163:
5 th European Congress of Virologyr
- Page 164 and 165:
5 th European Congress of VirologyR
- Page 166 and 167:
5 th European Congress of Virologyi
- Page 168 and 169:
5 th European Congress of VirologyI
- Page 170 and 171:
5 th European Congress of Virologyf
- Page 172 and 173:
5 th European Congress of Virologya
- Page 174 and 175:
5 th European Congress of VirologyS
- Page 176 and 177:
5 th European Congress of Virology1
- Page 178 and 179:
5 th European Congress of Virologyt
- Page 180 and 181:
5 th European Congress of VirologyV
- Page 182 and 183:
5 th European Congress of Virologyc
- Page 184 and 185:
5 th European Congress of Virologyw
- Page 186 and 187:
5 th European Congress of Virologyt
- Page 188 and 189:
5 th European Congress of Virologya
- Page 190 and 191:
5 th European Congress of VirologyA
- Page 192 and 193:
5 th European Congress of Virologyn
- Page 194 and 195:
5 th European Congress of Virologyi
- Page 196 and 197:
5 th European Congress of Virologyw
- Page 198 and 199:
5 th European Congress of VirologyT
- Page 200 and 201:
5 th European Congress of Virology(
- Page 202 and 203:
5 th European Congress of Virologya
- Page 204 and 205:
5 th European Congress of Virology1
- Page 206 and 207:
5 th European Congress of Virologyo
- Page 208 and 209:
5 th European Congress of VirologyI
- Page 210 and 211:
5 th European Congress of VirologyR
- Page 212 and 213:
5 th European Congress of Virologyw
- Page 214 and 215:
5 th European Congress of Virologyt
- Page 216 and 217: 5 th European Congress of Virologya
- Page 218 and 219: 5 th European Congress of Virologyp
- Page 220 and 221: 5 th European Congress of Virologya
- Page 222 and 223: 5 th European Congress of Virology(
- Page 224 and 225: 5 th European Congress of Virologyt
- Page 226 and 227: 5 th European Congress of Virologyn
- Page 228 and 229: 5 th European Congress of Virologyi
- Page 230 and 231: 5 th European Congress of Virologyo
- Page 232 and 233: 5 th European Congress of Virology2
- Page 234 and 235: 5 th European Congress of VirologyR
- Page 236 and 237: 5 th European Congress of Virology7
- Page 238 and 239: 5 th European Congress of VirologyR
- Page 240 and 241: 5 th European Congress of VirologyR
- Page 242 and 243: 5 th European Congress of Virologya
- Page 244 and 245: 5 th European Congress of Virologyc
- Page 246 and 247: 5 th European Congress of Virologya
- Page 248 and 249: 5 th European Congress of Virologyh
- Page 250 and 251: 5 th European Congress of Virology6
- Page 252 and 253: 5 th European Congress of VirologyC
- Page 254 and 255: 5 th European Congress of VirologyM
- Page 256 and 257: 5 th European Congress of Virologyi
- Page 258 and 259: 5 th European Congress of Virology2
- Page 260 and 261: 5 th European Congress of Virologyf
- Page 262 and 263: 5 th European Congress of VirologyR
- Page 264 and 265: 5 th European Congress of Virologyw
- Page 268 and 269: 5 th European Congress of VirologyI
- Page 270 and 271: 5 th European Congress of Virologyp
- Page 272 and 273: 5 th European Congress of Virologyu
- Page 274 and 275: 5 th European Congress of VirologyO
- Page 276 and 277: 5 th European Congress of Virologys
- Page 278 and 279: 5 th European Congress of Virology2
- Page 280 and 281: 5 th European Congress of Virologyf
- Page 282 and 283: 5 th European Congress of Virology2
- Page 284 and 285: 5 th European Congress of VirologyA
- Page 286 and 287: 5 th European Congress of VirologyI
- Page 288 and 289: 5 th European Congress of VirologyB
- Page 290 and 291: 5 th European Congress of VirologyD
- Page 292 and 293: 5 th European Congress of VirologyG
- Page 294 and 295: 5 th European Congress of VirologyJ
- Page 296 and 297: 5 th European Congress of VirologyL
- Page 298 and 299: 5 th European Congress of VirologyN
- Page 300 and 301: 5 th European Congress of VirologyR
- Page 302 and 303: 5 th European Congress of VirologyS
- Page 304 and 305: 5 th European Congress of VirologyW